Lexology April 1, 2024
On March 15, 2024, FDA’s medical product centers – CBER, CDER, and CDRH – along with the Office of Combination Products (OCP) published a paper outlining their key areas of focus for the development and use of artificial intelligence (AI) across the medical product life cycle. The paper, entitled “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” is intended by the Agency to “provide greater transparency regarding how FDA’s medical product Centers are collaborating to safeguard public health while fostering responsible and ethical innovation.” The FDA paper is the latest in series of informal statements from the Agency about the use of AI in the discovery, development, manufacturing, and commercialization of medical products, as...
Today's Sponsors
Today's Sponsor